All In Biotech

Drug Trial Radar · NCT03653520

Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)

Conscious Sedation Efficacy of the Novel Medication, MKO Melt (Midazolam, Ketamine, Ondansetron), During Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Aug 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 651 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

651

Actual

Start

Jun 28, 2017

Primary completion

Nov 2, 2017

Study completion Nov 4, 2017

Sponsor

Lead sponsor
Avanti AnesthesiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The investigators hypothesized that the combination of Valium, Tramadol and Zofran is superior to the substantially more expensive MKO melt in patient satisfaction after cataract surgery.

Conditions

  • Cataract

Interventions

  • DiazepamDrug

    5 or 10mg

  • TramadolDrug

    50mg or 100mg

  • OndansetronDrug

    1 or two tabs

  • MKO meltDrug

    1 or 2 MKO melts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patient who needed additional IV medication for cataract surgeryTime frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Memorial Hermann Kirby Glen Surgery Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.